Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
AstraZeneca said its lupus drug had shown superior results compared with a placebo in a clinical trial.
On the primary endpoint, lupus drug, anifrolumab, achieved meaningfully reduced disease activity at week 52, with 47.8% of patients receiving the drug responding compared with 31.5% of patients on placebo, the drugmaker said.
'There has only been one new medicine approved for systemic lupus erythematosus in the last 60 years, which is why we are so excited to see the positive TULIP 2 results,' said Mene Pangalos, executive vice president, BioPharmaceuticals R&D.
'There is now a strong body of evidence demonstrating the benefit of anifrolumab, and we look forward to bringing this potential new medicine to patients with systemic lupus erythematosus as soon as possible,' Pangalos added.